Literature DB >> 20688042

Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Rebecca V Anderson1, Deborah D Crane, Catharine M Bosio.   

Abstract

Protection against the intracellular bacterium Francisella tularensis within weeks of vaccination is thought to involve both cellular and humoral immune responses. However, the relative roles for cellular and humoral immunity in long lived protection against virulent F. tularensis are not well established. Here, we dissected the correlates of immunity to pulmonary infection with virulent F. tularensis strain SchuS4 in mice challenged 30 and 90 days after subcutaneous vaccination with LVS. Regardless of the time of challenge, LVS vaccination protected approximately 90% of SchuS4 infected animals. Surprisingly, control of bacterial replication in the lung during the first 7 days of infection was not required for survival of SchuS4 infection in vaccinated mice. Control and survival of virulent F. tularensis strain SchuS4 infection within 30 days of vaccination was associated with high titers of SchuS4 agglutinating antibodies, and IFN-γ production by multiple cell types in both the lung and spleen. In contrast, survival of SchuS4 infection 90 days after vaccination was correlated only with IFN-γ producing splenocytes and activated T cells in the spleen. Together these data demonstrate that functional agglutinating antibodies and strong mucosal immunity are correlated with early control of pulmonary infections with virulent F. tularensis. However, early mucosal immunity may not be required to survive F. tularensis infection. Instead, survival of SchuS4 infection at extended time points after immunization was only associated with production of IFN-γ and activation of T cells in peripheral organs.
Copyright © 2010. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688042      PMCID: PMC2939155          DOI: 10.1016/j.vaccine.2010.07.072

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity.

Authors:  C M Bosio; K L Elkins
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine.

Authors:  H T EIGELSBACH; J J TULIS; E L OVERHOLT; W R GRIFFITH
Journal:  Proc Soc Exp Biol Med       Date:  1961-12

3.  Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma.

Authors:  Karen L Elkins; Susan M Colombini; Anda I Meierovics; May C Chu; Alicia Y Chou; Siobhán C Cowley
Journal:  Microbes Infect       Date:  2009-09-23       Impact factor: 2.700

4.  Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS.

Authors:  D Yee; T R Rhinehart-Jones; K L Elkins
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

5.  Minimal requirements for murine resistance to infection with Francisella tularensis LVS.

Authors:  K L Elkins; T R Rhinehart-Jones; S J Culkin; D Yee; R K Winegar
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

6.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

7.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

8.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

9.  Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica.

Authors:  Stephan Stenmark; Helena Lindgren; Arne Tärnvik; Anders Sjöstedt
Journal:  Microb Pathog       Date:  2003-08       Impact factor: 3.738

10.  Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients.

Authors:  I M Orme; F M Collins
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  23 in total

1.  TLR4-dependent activation of inflammatory cytokine response in macrophages by Francisella elongation factor Tu.

Authors:  Jyotika Sharma; Bibhuti B Mishra; Qun Li; Judy M Teale
Journal:  Cell Immunol       Date:  2011-03-29       Impact factor: 4.868

2.  Hematopoietic MyD88 and IL-18 are essential for IFN-γ-dependent restriction of type A Francisella tularensis infection.

Authors:  Jerod A Skyberg; Carolyn A Lacey
Journal:  J Leukoc Biol       Date:  2017-09-26       Impact factor: 4.962

3.  Temporal Requirement for Pulmonary Resident and Circulating T Cells during Virulent Francisella tularensis Infection.

Authors:  Lydia M Roberts; Tara D Wehrly; Robin M Ireland; Deborah D Crane; Dana P Scott; Catharine M Bosio
Journal:  J Immunol       Date:  2018-07-06       Impact factor: 5.422

4.  Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.

Authors:  Michael D Valentino; Zachary J Maben; Lucinda L Hensley; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Immunology       Date:  2011-01-07       Impact factor: 7.397

5.  Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.

Authors:  Amanda J Griffin; Deborah D Crane; Tara D Wehrly; Catharine M Bosio
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

6.  Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Tara D Wehrly; Ian Leighton; Patrick Hanley; Jamie Lovaglio; Brian J Smith; Catharine M Bosio
Journal:  J Immunol       Date:  2022-02-11       Impact factor: 5.422

7.  B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Authors:  Deborah D Crane; Amanda J Griffin; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

8.  Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Deborah D Crane; Tara D Wehrly; Joshua R Fletcher; Bradley D Jones; Catharine M Bosio
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

9.  IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection.

Authors:  Lydia M Roberts; John S Davies; Gregory D Sempowski; Jeffrey A Frelinger
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

Review 10.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.